A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)

Conditions

• Oesophageal Squamous Cell Carcinoma

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• I-DXd — BIOLOGICAL
  IV Infusion
• Rescue Medication — DRUG
  Includes 5-HT3 receptor antagonist, NK-1 receptor antagonist, and corticosteroid, administered per approved product label

Study Details

The purpose of this trial is to assess if ifinatamab deruxtecan (I-DXd) can treat esophageal squamous cell carcinoma (ESCC). I-DXd is an antibody-drug conjugate (ADC). An ADC attaches to a protein on cancer cells and delivers treatment to destroy those cells. The goal of this trial is to learn how many participants who receive I-DXd have the cancer respond, which means the cancer gets smaller or goes away.

Key Dates

First listed

Feb 12, 2026

Start date

Mar 27, 2026

Status verified

Jul 2026

Primary completion

Jun 12, 2027

Completion

Jun 12, 2028

Study Design

Enrollment

60 participants (estimated)

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Arms

• Experimental: I-DXd
  Participants will be administered I-DXd every 3 weeks until progressive disease or discontinuation criteria are met.

Primary Outcome Measure

Objective Response Rate (ORR) [ Time Frame: Up to approximately 14 months ]

Central Contacts

• Toll Free Number
  1-888-577-8839
  [email protected]

Locations (1)

Find similar trials in Pittsburgh, PA